Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Disease
- Therapeutic
- DNA
- Fibrosis
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245713
License Grant
The Italian Licensor grants to the UK Licensee a worldwide, exclusive license, including the right to grant sublicenses, under the Licensed Patents, to research, develop, make, have made, use, offer for sale, sell, have sold and import Licensed Products for any and all uses in the Field in the Territory.
License Property
Licensed Product means any product or service incorporating Milciclib as active ingredient for the treatment of cancer and inflammatory diseases.
Licensed Patent 8981089B2 PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS. Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
Licensed Product means any product or service incorporating Milciclib as active ingredient for the treatment of metastatic HCC, an aggressive type of liver cancer.
Field of Use
The Licensee will have the exclusive right to develop and commercialize the Licensed Product for all diagnostic and therapeutic uses, including cancer and inflammatory diseases.
IPSCIO Record ID: 243433
License Grant
For the Licensed IP Rights, the Italian Licensor grants an exclusive license under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field, and, Licensor grants a non-exclusive license under any patent, know-how or other intellectual property rights Controlled by Licensor to research and to develop, make, have made, use, offer for sale, sell and import any diagnostic product for one or more of the Exclusive Targets.
License Property
Product(s) shall mean any product that incorporates one or both of the APls and if made, used, sold, offered for sale or imported absent the license granted hereunder would infringe a Valid Claim, or that otherwise uses or incorporates the Licensor Know-How.
The patent is for Substituted Indazole Derivatives Active as Kinase Inhibitors.
RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during transfection (RET) tyrosine kinase. Each of these programs is in preclinical development for the potential treatment of multiple cancers.
Loss of cell cycle control is a hallmark of cancer, and interfering with the DNA replication process is a proven strategy for cancer therapy. Currently available chemotherapies, such as anti-metabolites, topoisomerase inhibitors, and crosslinking and intercalating agents, classically take a broad-based approach to inhibiting the elongation step of DNA replication. This strategy has led to successful treatment outcomes, but off-target effects can lead to dose-limiting toxicity. Cdc7 is a serine/threonine protein kinase essential for the initiation step of DNA replication during the synthesis (S) phase.
Field of Use
The Field shall mean all fields of use, including without limitation the diagnosis, prevention or treatment of any disease, state or condition in humans or other animals.
Licensee has capabilities in the development of oncology products.
IPSCIO Record ID: 283332
License Grant
Licensor grants an exclusive license, to make, use, sell, offer to sell, import, and export the rights afforded under the Patents in the Field and in the Territory.
License Property
The patents are for PKC Delta Inhibitors for use as Therapeutics.
Licensee acquired all rights, including composition of matter patents (the “PKCd Patentsâ€), and preclinical study data to a novel therapeutic technology platform, known as protein kinase C delta (PKCd) inhibitors, which represents a unique, highly-targeted approach to treat cancer and to boost the immune system.
Field of Use
Field means the prevention and/or treatment of fibrosis and neoplastic diseases and disorders in humans and animals.
IPSCIO Record ID: 27879
License Grant
Licensors hereby grant to Licensee an exclusive, worldwide license, including the right to sublicense, under Licensor Patent Rights and Future Patent Rights, to make, have made, use, sell, import and export Products.
License Property
Methods for Therapy Sensitization by Inhibition of Jun Kinase Patent Attorney Docket No. P-UR 2590 (2841302).
Field of Use
The term Field shall mean methods for therapy sensitization by the inhibition of jun kinase and/or the claims specified in the patent application.
IPSCIO Record ID: 266704
License Grant
Licensor grants to Licensee a royalty bearing license in the Territory in the Field, with the right to grant sublicenses, under the Compound Patent Rights, which Compound Patent Rights license shall be exclusive and the Licensor Know-How, which Licensor Know-How license shall be non-exclusive, to Develop, Manufacture, have Manufactured, use, import, export and Commercialize the Licensed Compounds and the Licensed Products in the Field in the Territory during the Term.
License Property
The patents include Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose) polymerase(P ARP) inhibitors; Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors; Pharmaceutically acceptable salts of 2-{ 4-[(3S)-piperidin-3-yl]phenyl} -2-indazole-7-carboxamide; and, Pyridazinone derivatives as PARP inhibitors.
Licensed Compounds shall mean those certain Licensor compounds currently known as M_-4827 with the following chemical name 2 [4 (3S) 3 PIPERIDINYLPHENYL] 2H INDAZOLE 7 CARBOXAMIDE and M_-2512 with the following chemical name 6 (3 [(4 CYCLOPENTYL 3 OXYPIPERAZIN 1 XL)CARBONYL] 4 FLUOROBENZYL] 4,5 DIMETHYLPYRIDAZIN 3(21-l) ONE], and with respect to both, shall include any pharmaceutically acceptable salt, polymorph, crystal form, prodrug or solvate thereof that but for the license granted, would infringe the Compound Patent Rights.
M_-4827, also known as Niraparib, is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor in cancer patients as a monotherapy.
M_-2512 is the backup PARP inhibitor compound.
Field of Use
This agreement includes the development of niraparib for the treatment of tumor. Niraparib is aprescribed PARP inhibitor to treat cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
